NGS for Precision Medicine in Hematologic Disorders

Next-generation sequencing (NGS) has revolutionized hematology by enabling comprehensive analysis of the genetic landscape of hematologic malignancies and inherited blood disorders. It allows high-throughput, simultaneous sequencing of a very large number of genes, providing insights into genetic mutations, structural variations, and epigenetic alterations. In malignancies such as leukemia, lymphoma, and myelodysplastic syndromes, NGS facilitates the identification of diagnostic markers, risk stratification, and detection of minimal residual disease (MRD). This precision guides therapeutic decisions, including targeted therapies, by uncovering actionable mutations like FLT3, NPM1, and IDH1/2. Furthermore, NGS panels allow for the dynamic monitoring of clonal evolution during disease progression and treatment. In inherited hematologic disorders, such as thalassemia, sickle cell anemia, and hemophilia, NGS enhances diagnostic accuracy by pinpointing causative mutations and identifying carriers. Whole-genome and whole-exome sequencing are particularly valuable for diagnosing complex conditions (such as rare inherited hemolytic disorders, idiopathic bone marrow failure syndromes, inherited, and platelet function disorders, which are not detected by routine tests) and uncovering novel gene variants. Additionally, NGS supports bone marrow transplantation by refining donor selection through high-resolution HLA typing. Technological advancements, including single-cell sequencing and methylation profiling, have expanded the utility of NGS in hematology, enabling the study of tumor heterogeneity and epigenetic regulation. Despite its transformative impact, challenges remain, including high costs, data interpretation complexity, and the need for robust bioinformatics pipelines. Ethical considerations related to incidental findings and genetic counselling also require attention. NGS has become an integral tool in hematology, driving precision medicine and advancing our understanding of blood disorders. As technology evolves, its applications are expected to expand, further improving patient outcomes through personalized care.